Disc Medicine Inc., a clinical-stage biopharmaceutical company, has announced the initiation of the APOLLO trial, a confirmatory clinical study for their lead program, bitopertin, in adults and adolescents with erythropoietic protoporphyria $(EPP.UK)$. This double-blind, placebo-controlled trial aims to support the conversion of a U.S. accelerated approval to full approval, with plans to submit a New Drug Application (NDA) in the second half of 2025. The APOLLO trial is part of Disc Medicine's ongoing efforts to develop novel treatments for serious hematologic diseases. Additionally, the company is preparing to launch a Phase 2 study of DISC-3405 for polycythemia vera (PV) in the first half of 2025. With a strong financial foundation, Disc Medicine remains well-positioned to advance its pipeline and commercial preparation efforts.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.